Proteome editing
Powered by AI,
Driven by Biology
With the proteome as our focus, our mission is to integrate AI, computation, and biological automation
to accelerate the design of novel proteome editors.
1910
Beginning
1976
1st report of sickle cell anemia in the United States
1990
2003
2021
We aim to solve diseases impacted by modulating protein interactions
Most conditions have few treatment options, and those available often cause frequent complications and offer minimal benefit
Current therapies lack the ability to specifically target mutant, isoform and post-translational forms of proteins
Driven by our deep learning AI/ML model, we have developed a modular and programmable platform for targeted protein degradation
By applying revolutionary insights, we can rationally design our core therapeutics at significantly faster rates than traditional approaches
Our Science:
Chimeric Ligands for Induced Proximity (CLIPs)
Precise in vivo proteome engineering to develop safe, breakthrough therapies that have the potential to reach more patients
Our technology rest on three key pillars
Deep learning computational platform
Binder design driven by purely sequence-based approach to generate novel effector proteins for therapeutic application
Target-specific, programmable payload design
mRNA encoded CLIPs to enable precise proteome editing
Compatibility with a variety of delivery systems
Lipid nanoparticle-based systems for safe, repeat in vivo dosing
AAV delivery for appropriate targets and more
Chimeric Ligands for Induced Proximity
Our precise in vivo programmable technology has several potential competitive advantages for developing best-in-class medicines:
1
Ability to target isoforms and post-translationally modified proteins
2
Computational platform drives rapid development cycle with high affinity binders
3
Cell-type specificity to disease-relevant cells, if required
4
Tunability to fit safety and efficacy bars depending on disease indication
5
Potential administration in outpatient setting with repeat dosing
6
Potential for multi-target, high-dose therapeutics and application to other protein-modulating processes
Founding Team
We are an entrepreneurial team of extraordinary scientists, engineers, and entrepreneurs, purpose-built to meld cutting-edge know-how from deep learning architecture and drug discovery.
Joseph Jacobson, PhD, is an Associate Professor at MIT, the founding member of the MIT Center for Bits and Atoms, and Director of the Molecular Machines Group at The MIT Media Laboratory. Dr. Jacobson has authored over 70 peer reviewed papers and conference proceedings in the fields of femotosecond lasers, quantum optics, printed electronics, and synthetic biology and has 115 issued U.S. patents. He is the recipient of a number of prizes and awards including a 1999 Technology Review TR100 Award for the top 100 Innovators under 35, The 2000 Gutenberg Prize (Germany), a 2001 Discover Award, The 2013 Exner Medal and 2016 induction into the U.S. Patent Office’s Inventors Hall of Fame.
He received his PhD in physics from MIT, was a postdoctoral fellow at Stanford, and is the co-founder of e-Ink, Gen9, Inc., Kovio, and DeepCure.
Mathew Barnett, MBA, leads the business development for UbiquiTx. He is a former hedge fund analyst and investment banker at Merrill Lynch participating in several billion dollars of acquisition transactions.. He received his MBA at the Columbia Business School and The Wharton School. He leads the firm’s commercial efforts.
CEO/Co-Founder
Scientific Co-Founder
Matthew DeLisa, PhD, is a Scientific Co-founder of UbiquiTx and the William L. Lewis Professor of Engineering at Cornell University. Dr. DeLisa received his B.S. in Chemical Engineering from the University of Connecticut in 1996 and his Ph.D. in Chemical Engineering from the University of Maryland in 2001, followed by postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. Dr. DeLisa focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis - folding and assembly, membrane translocation, and post-translational modifications - in the complex environment of a living cell. His contributions include the invention of numerous commercially important technologies for facilitating the discovery, design, and manufacture of human drugs, and seminal discoveries in the areas of cellular protein folding and protein translocation. Dr. Delisa is a co-founder of Swiftscale (acquired), Glycobia, Versatope and MacImmune.
Scientific Co-Founder
Joseph Jacobson, Ph.D., is a Scientific Co-founder of UbiquiTx and an Associate Professor at MIT, the founding member of the MIT Center for Bits and Atoms, and Director of the Molecular Machines Group at the MIT Media Laboratory. Dr. Jacobson has authored over 70 peer-reviewed and conference proceedings in the fields of femtosecond lasers, quantum optics, printed electronics, and synthetic biology and has 115 issued U.S. patents. He is the recipient of a number of prizes and awards including a 1999 Technology Review TR100 Award for the top 100 Innovators under 35, the 2000 Gutenberg Prize (Germany), a 2001 Discover Award, The 2013 Exner Medal and 2016 Induction ito the U.S. Patent Office's Inventors Hall of Fame. He received his PhD in physics from MIT, was a postdoctoral fellow at Stanford, and the the co-founder of e-Ink (acquired), Gen9 Inc.m Kovio and Deepcure.
Luiz Miguel Camargo, PhD, the Chief Scientific Officer of UbiquiTx. Miguel was formerly head of the targeted protein degradation group at UCB. Miguel has more than 20 years of experience in drug discovery, with much of his work being motivated by translating data sciences into real-world applications, He has led innovative data efforts at Merck, Novartis, and UCB working on translational medicine, target & biomarker discovery, lead identification & optimization, phenotypic screens, and efforts to better define disease using electronic medical records.
In addition to his role as computational biologist, Miguel has also led multidisciplinary drug discovery teams, as well as academic and industrial collaborations. At UCB, Miguel was responsible for identifying key and disruptive technologies by fostering partnerships with academic institutes, biotech companies, and venture funds. Miguel was deeply involved in building UCB’s research presence in the US and was responsible for building UCB’s Targeted Protein Degradation Platform that spans all three UCB research hubs (Belgium, UK, and US).
Miguel received his PhD in bioinformatics from the University of Cambridge, and has several publications in leading journals.
CSO/Co-Founder
Scientific Co-Founder
Pranam Chatterjee, PhD, is a Scientific Co-Founder of UbiquiTx and an Assistant Professor of Biomedical Engineering, Biostatistics & Bioinformatics and Computer Science at Duke University. Research in his Programmable Biology Group exists at the interface of computational design and experimental engineering, specifically employing state-of-the-art algorithmic methods to engineer programmable proteins for applications in genome, proteome, and cell engineering. A PhD graduate of the MIT Media Lab and a recent postdoctoral fellow at Harvard, he developed robust genome editing technologies that represent some of the broadest, safest, and most effective CRISPR enzymes to date. More recently, Dr. Chatterjee’s research has extended to the emergent field of “proteome” editing, where his team leverages structure and sequence-based generative design to engineer peptide-guided therapeutics that target and modulate pathogenic proteins in a CRISPR-analogous manner, including those implicated in viral diseases and cancer. His established expertise in machine learning are further being applied to develop transcription factor-based stem cell differentiation protocols for reproductive cell types, including primordial germ cells and oocytes.
He is the co-founder of Gameto, Inc.
Mathew Barnett, MBA, leads the business development for UbiquiTx. He is a former hedge fund analyst and investment banker at Merrill Lynch participating in several billion dollars of acquisition transactions.. He received his MBA at the Columbia Business School and The Wharton School. He leads the firm’s commercial efforts.
Scientific Advisory Board
Hao Zhu MD,/Ph.D –
Hao Zhu earned his bachelor’s degree in biology from Duke University, followed by an M.D. from Harvard Medical School and MIT. He underwent training in internal medicine at University of California, San Francisco, and medical oncology at the Dana-Farber Cancer Institute. From 2008 to 2012, Dr. Zhu performed postdoctoral research at Boston Children’s Hospital. In 2012, he joined the faculty of the Children’s Medical Center Research Institute at UT Southwestern. He is also an attending physician in the Multidisciplinary Liver Cancer Clinic at Parkland Memorial Hospital.
Dr. Zhu is the recipient of a Burroughs Welcome Career Award for Medical Scientists (2012), a CPRIT Scholar Award (2012), a Stand Up To Cancer Innovative Research Grant (2016), and Mark Foundation Emerging Leader Award (2021).
Scott Friedman, MD
Dr. Friedman is the Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases, at the Icahn School of Medicine at Mount Sinai. Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai. His pioneering research in hepatic fibrosis supported by NIH since 1986, combined with mentoring of over 80 trainees have contributed to the emergence of fibrosis as an exciting new therapeutic area in hepatology. Dr. Friedman was a Senior Fulbright Scholar at the Weizmann Institute, Israel in 1995 and President of the AASLD in 2009. He has received the International Hans Popper and the EASL International Recognition Awards, and is a Fellow of the AASLD, AGA, ACP and AAAS.
Richard Finn, MD
Dr. Richard Finn is a professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology. He was an undergraduate at UCLA where he was involved with early laboratory studies investigating the HER2 oncogene and the development of monoclonal antibodies to this target in breast cancer with Dr. Dennis Slamon. He participated in the pre-clinical studies that defined the clinical candidate that eventually humanized and became the FDA approved agent trastuzumab (Herceptin). He went on to medical school at USC then returned to UCLA for his clinical training in Internal Medicine and then Hematology/ Oncology.
He currently splits his time between patient care and directing the Translational Research Laboratory in the Division of Hematology/Oncology. His research interests are focused in the development of targeted therapeutics for solid tumors across histologies to support the larger efforts of the departmen
Paul Monga, MD
Dr. Monga is the Chair for Experimental Pathology, Vice Chair and Chief of Division of Experimental Pathology, Professor of Pathology (Division of Experimental Pathology), Professor of Medicine (Division of Gastroenterology, Hepatology & Nutrition), Assistant Dean for Medical Scientist Training Program, Director of Cellular Approaches to Tissue Engineering & Regeneration (CATER) Program, Associate Director of the University of Pittsburgh Drug Discovery Institute (UPDDI), and Director of the Pittsburgh Liver Research Center.
For around 21 years, Dr. Monga’s research has focused on understanding the cellular and molecular basis of liver health and disease. Specifically, my lab has a longstanding interest in understanding the role of cellular and molecular signaling in liver development, regeneration, inflammation, injury, fibrosis and tumorigenesis. One major focus of the Dr. Monga’s lab is to understand subsets of human HCC through better and more representative disease modeling. Dr. Monga’s lab has focused on elucidating role and regulation of complex cell-molecule circuitry of the highly relevant pathways such as Wnt/ ?-catenin in liver physiology especially in metabolic zonation and regeneration, which we believe will be prudent for the continued success of hepatic regenerative medicine as a discipline and expected to yield better therapies for patients with chronic liver disease, cirrhosis and ESLD.
Dan Peer, Ph.D
Dr. Peer is the director of the Laboratory of Precision NanoMedicine at Tel Aviv University. He is also the Vice President for Research and Development at Tel Aviv University. His lab works in the interface of basic and translational science. In addition, Prof. Peer is the Founder and Managing Director of the SPARK Tel Aviv, Center for Translational Medicine. Moreover, Prof. Peer is on the Scientific Advisory Board of numerous international companies and an invited keynote speaker in many conferences.
Prof. Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using targeted nanocarriers to the immune system and he pioneered the use of RNA interference for drug discovery in immune cells. In addition, his lab was the first to show systemic, cell- specific delivery of modified mRNA expressing therapeutic proteins that has enormous implications in cancer, inflammation and infectious diseases. Prof. Peer is one of the pioneers in the use of molecular medicines (gene silencing, gene expression and gene editing) for therapeutics and diseases management.
Publications
Get in Touch
